SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update

Robust enrollment continues in Phase 2b VVC trial with top-line data expected in mid-2018 IV SCY-078 program advancing, with liposomal IV formulation to be tested in a Phase 1 study in the third quarter of 2018 Completion of recent $30.0 million equity offering strengthens Company’s cash position


Leave a Reply

Your email address will not be published.